文献速递浆细胞疾病

抗有丝分裂剂PTC-028和PTC596在多发性骨髓瘤临床前模型中显示强效活性但挑战BMI-1作为必需肿瘤基因的作用

The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene.
PubMed 文献 · Br J Haematol · 2020-03-30

本研究在多发性骨髓瘤(MM)的体外和体内临床前模型中评估BMI-1调节剂PTC-028和PTC596,发现两者具有强效抗MM活性,但BMI-1对药物活性和MM细胞生长并非必需,抗MM机制与有丝分裂阻滞伴MCL-1丢失相关。

要点

  • PTC-028和PTC596在体外和体内MM模型(含耐药及基质支持模型)中显示强效活性。
  • BMI-1对BMI-1调节剂的活性和MM细胞生长并非必需。
  • 抗MM机制与有丝分裂阻滞伴MCL-1丢失及MYC、AKT信号受损相关。

核心结论

  • PTC-028和PTC596是强效抗有丝分裂剂,临床前活性支持其快速转化进入临床试验。
  • 结果对BMI-1作为必需MM基因的假设提出质疑。

研究设计与样本

  • 研究为临床前评估,在体外和体内多发性骨髓瘤模型中评价BMI-1调节剂PTC-028和PTC596。

主要发现

  • PTC-028和PTC596在包括耐药和基质支持模型在内的体外及体内模型中显示强效活性。
  • PTC-028和PTC596处理下调MM细胞BMI-1蛋白水平,且与药物活性相关。
  • BMI-1对BMI-1调节剂的活性和MM细胞生长并非必需。
  • 抗MM机制与有丝分裂阻滞伴髓细胞白血病-1(MCL-1)丢失相关,并发现MYC和AKT信号活性受损。
  • 在5TGM.1体内模型中,PTC596治疗后观察到MM完全清除,表观遗传化合物和BH3模拟物被确定为有前景的联合伙伴。

临床怎么用

  • 原文结论认为BMI-1调节剂具有鼓舞人心的临床前活性,支持其快速转化进入临床试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Future progress in the treatment of multiple myeloma (MM) requires both the characterisation of key drivers of the disease and novel, innovative approaches to tackle these vulnerabilities. The present study focussed on the pre-clinical evaluation of a novel drug class, BMI-1 modulators, in MM. We demonstrate potent activity of PTC-028 and PTC596 in a comprehensive set of in vitro and in vivo models, including models of drug resistance and stromal support. Treatment of MM cells with PTC-028 and PTC596 downregulated BMI-1 protein levels, which was found to correlate with drug activity. Surprisingly, BMI-1 was dispensable for the activity of BMI-1 modulators and MM cell growth. Our data rather point to mitotic arrest accompanied by myeloid cell leukaemia-1 (MCL-1) loss as key anti-MM mechanisms and reveal impaired MYC and AKT signalling activity due to BMI-1 modulator treatment. Moreover, we observed a complete eradication of MM after PTC596 treatment in the 5TGM.1 in vivo model and define epigenetic compounds and B cell leukaemia/lymphoma 2 homology domain 3 (BH3) mimetics as promising combination partners. These results bring into question the postulated role of BMI-1 as an essential MM gene and confirm BMI-1 modulators as potent anti-mitotic agents with encouraging pre-clinical activity that supports their rapid translation into clinical trials.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Bolomsky A, Muller J, Stangelberger K, et al. The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene. Br J Haematol. 2020. PMID: 32232850. doi:10.1111/bjh.16595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。